The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
نویسندگان
چکیده
منابع مشابه
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
Lung cancer is the leading cause of cancer-related deaths in men and women [1]. Almost 80% of bronchogenic carcinomas are of the non-small cell lung cancer (NSCLC) subtype and approximately half of the patients with newly diagnosed NSCLC present with metastatic disease. The median overall survival (OS) for these patients is approximately 10 months and the 5-year survival rates are less than 1% ...
متن کاملTowards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data
PD-L1 is a ligand that upon binding to its receptor (PD-1) on T-cells leads to T-cell anergy/and or apoptosis [1,2]. We have shown that PD-L1 is expressed in breast cancer where its expression correlates with estrogen receptor (ER) negativity [3]. To understand the mechanism of the constitutive expression of PD-L1 in tumor cells of ER negative cells we used gene-in and out approach, large scale...
متن کاملThe PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were used to study PD-1/PD-L1 expression. Functional assays were used to determine the involvement of the PD-1/PD-L1 axis in T-cell responses. PD-1...
متن کاملImmune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immu...
متن کاملTargeting PD-1/PD-L1 in lung cancer: current perspectives
Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cells
سال: 2021
ISSN: 2073-4409
DOI: 10.3390/cells10061510